二甲基硅油/氢氧化铝/氢氧化镁(Dimethicone/Aluminum hydroxide/magnesium dihydroxide) - 药物靶点：Proton pump_在研适应症：十二指肠溃疡，胃肠胀气，胃溃疡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Gelusil、Mintox

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂

治疗领域

消化系统疾病其他疾病

在研适应症

十二指肠溃疡胃肠胀气胃溃疡

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式AlH3MgO4Si

InChIKeyAUNJGAJRTBKKGS-UHFFFAOYSA-K

CAS号8077-28-9

关联

3

项与二甲基硅油/氢氧化铝/氢氧化镁相关的临床试验

NCT01982201

/ Completed临床1期

A Phase 1, Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interaction Between Lesinurad and Calcium Carbonate and Aluminum/Magnesium Hydroxide-Containing Antacids in Healthy Adult Male Subjects

This study will assess the potential effects of calcium carbonate and aluminum/magnesium hydroxide-containing antacids on the pharmacokinetics (PK) and pharmacodynamics (PD) of lesinurad in healthy, adult male subjects.

开始日期2013-11-01

申办/合作机构

Ardea Biosciences, Inc.

NCT01622673

/ Completed临床1期

A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen

This study will evaluate: (1) the effect of co-administration of single doses of calcium carbonate antacid and magnesium/aluminum hydroxide antacid on the steady-state plasma pharmacokinetic profile of raltegravir in human immunodeficiency virus (HIV)-infected participants; and (2) the effect of staggered dosing of a single dose of a magnesium/aluminum hydroxide antacid 2 hours before and 2 hours after administration of raltegravir on the steady-state plasma pharmacokinetic profile of raltegravir in the same participants.
The study will determine whether (1) the C12hrs of steady-state raltegravir after co-administration of single doses of calcium carbonate antacid is decreased to a clinically meaningful degree compared with C12hrs after administration of raltegravir alone; and whether (2) the C12hrs of steady-state raltegravir after co-administration of a single dose of magnesium/aluminum hydroxide antacid is decreased to a clinically meaningful degree compared with the C12hrs after administration of raltegravir alone.

开始日期2012-06-01

申办/合作机构

Merck Sharp & Dohme Corp.

NCT00703534

/ Completed临床2期

Validation of Patient-reported Outcomes Measures for the Assessment of GERD Symptoms and Their Subsequent Impact on Patients With Partial Response to Proton Pump Inhibitor (PPI) Treatment in a Two Part Multi-center Phase IIa Study Including a Four Week Randomised, Double-blind, Placebo-controlled, Parallel-group Treatment Period

This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).

开始日期2008-05-01

申办/合作机构

AstraZeneca PLC

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的临床结果

登录后查看更多信息

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的转化医学

登录后查看更多信息

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的专利（医药）

登录后查看更多信息

65

项与二甲基硅油/氢氧化铝/氢氧化镁相关的文献（医药）

2023-10-01·Chemistry & Biodiversity

Quantification of Phytochemicals and Metal Ions as well as the Determination of Volatile Compounds, Antioxidant, Antimicrobial and Antacid Activities of the Mimosa pudica L. Leaf: Exploration of Neglected and Under‐Utilized Part

Article

作者: Rawat, Hemant ; Prasad, Shyam Baboo ; Ramamurthy, Praveen C ; Singh, Simranjeet ; Jha, Sudhanshu Kumar ; Webster, Thomas J ; Gandhi, Ms Yashika ; Mishra, Sujeet K ; Kumar, Vijay ; Singh, Arjun ; Mrkute, Akshada ; Singh, Ravindra ; Grewal, Jyotika ; Gupta, Akhil ; Charde, Vaibhav ; Tandon, Smriti ; Singh, Gagandeep ; Srikanth, Narayan ; Narasimhaji, Ch Venkata ; Acharya, Rabinarayan ; Soni, Hemant

AbstractMimosa pudica L. (MP) is well‐known plant in traditional medicinal system, especially in India. Unfortunately, leaves of MP are less explored. To determine the food and nutritional value of the neglected part of Mimosa pudica L. (MP), that is MP leaves, phytochemicals and metal ions of MP were quantified by newly developed HPLC and ICPOES‐based methods. The content of phytochemicals observed using HPLC analysis for chlorogenic acid, catechin, and epicatechin was 141.823 (±8.171), 666.621 (±11.432), and 293.175 (±12.743) μg/g, respectively. Using GC/MS/MS analysis, fatty acid like oleic acid were identified. In ICP‐OES analysis, a significant content of Na, K, Ca, Cu, Fe, Mg, Mn, and Zn was observed. The observed TPC and TFC for MP leaf extracts was 44.327 (±1.041) mg GAE/ g of wt. and 214.217 (±4.372) mg QCE/ g of wt., respectively. The DPPH assay depicted a strong antioxidant activity of MP leaf extracts with IC50 values of 0.796 (±0.081) mg/mL and a TEAC value of 0.0356 (±0.0003). A significant antacid activity (666 mg MP+400 mg CaCO3 >400 mg CaCO3 ≫666 mg Gelusil) of MP leaves was noticed. The methanolic extract of MP leaves demonstrated anti‐microbial activity against Staphylococcus aureus (15±2mm), Pseudomonas aeruginosa (12±2mm) and Escherichia coli (10±2mm). In silico studies confirmed the in vitro results obtained for antioxidant, antiacid, and anti‐microbial activities. In addition, in silico studies revealed the anti‐cancerous and anti‐inflammatory potential of the MP leaves. In summary, this study demonstrated the medicinal significance of MP leaves and the conversion of agro‐waste or the under‐utilized part of MP into pharmaceutical potent materials. Consequently, the present study highlighted that MP leaves alone have medicinal importance with good nutritional utility and possess large promise in the pharma industry along with improving bio‐valorization and the environment.

2016-08-01·Journal of Pharmaceutical Sciences3区 · 医学

Water Determination in Solid Pharmaceutical Products Utilizing Ionic Liquids and Headspace Gas Chromatography

3区 · 医学

Article

作者: Armstrong, Daniel W ; Frink, Lillian A

A rapid, accurate, and precise headspace gas chromatographic (HSGC) analytical method was developed for the detection and quantification of water in drug products. The analysis is able to be performed in 10 min and automated. The HSGC method used an ionic liquid (IL) based open tubular capillary gas chromatographic column to increase the ruggedness of this method and provide improved peak shapes for water. Due to the ionic liquids low vapor pressure, unique physiochemical properties, and high thermal stability, they also make idea solvents for HSGC. Unlike Karl Fischer titration methods, this HSGC method is not affected by side reactions. The developed method was shown to be broadly applicable. The water content in 12 different samples was found to range from 1%-7% water. The use of HSGC was highly sensitive and only required 10 mg of sample. In addition, it was found to have greater precision and accuracy than Karl Fischer titration and greater precision and speed than loss on drying.

2015-02-01·Current Medical Research and Opinion4区 · 医学

Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials

4区 · 医学

Article

作者: Hugo, Vincent ; Nagy, Peter ; Johnson, David A. ; Le Moigne, Anne

OBJECTIVETo investigate the resolution of heartburn and gastroesophageal reflux disease (GERD)-related sleep disturbances during the first 14 days of treatment with esomeprazole 20 mg compared to placebo in subjects with frequent nighttime heartburn and GERD-related sleep disturbances.RESEARCH DESIGN AND METHODSThis was a post hoc analysis of 2 week data from two previously published, similarly designed randomized, placebo-controlled trials of 4 weeks' duration comparing esomeprazole 20 mg, 40 mg (one study), and placebo. Inclusion and exclusion criteria for both trials were the same.CLINICAL TRIAL REGISTRATIONNCT00628342; NCT00660660.MAIN OUTCOME MEASURESThe main outcome measures for this analysis were the resolution and/or relief of GERD-related sleep disturbances during 2 weeks of treatment with esomeprazole 20 mg or placebo. Resolution and/or relief of heartburn symptoms were also measured.RESULTSIn trial 1, 455 subjects were randomized, with 225 and 229 receiving esomeprazole 20 mg and placebo, respectively. In trial 2, 276 subjects were randomized, with 142 and 132 receiving esomeprazole and placebo, respectively. After 2 weeks, significantly more subjects who received esomeprazole 20 mg (50.5% [95% confidence interval: 43.8%-57.1%] and 39.4% [31.2%-47.6%] in trials 1 and 2, respectively) had resolution of sleep disturbances compared to placebo (19.9% [14.6%-25.2%] and 16.0% [9.6%-22.4%], respectively; p < 0.0001 for both trials). The median time to resolution of sleep disturbances with esomeprazole 20 mg was 1 day in both trials. After 2 weeks, significantly more subjects receiving esomeprazole 20 mg (32.3% [26.1%-38.5%] and 26.3% [18.9%-33.6%] in trials 1 and 2, respectively) had resolution of nighttime heartburn symptoms compared to placebo (5.4% [2.4%-8.4%] and 4.8% [1.1%-8.5%], respectively; p < 0.0001 for both trials).CONCLUSIONSEsomeprazole 20 mg significantly and effectively reduced nighttime heartburn and GERD-related sleep disturbances in the first 2 weeks of treatment compared to placebo, with rapid resolution of sleep disturbances in the first days of treatment.

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
十二指肠溃疡	中国	-	-
胃肠胀气	中国	-	-
胃溃疡	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00703534 (C27, CTgov)	临床2期	胃食管反流 \| 胃灼热	478	Gelusil®+AZD3355 (AZD3355)	鏇顧構製壓顧網糧憲網(繭網衊淵襯網鹹選築鬱) = 廠築鬱蓋窪簾窪鑰範襯鏇鹽積淵壓鹹廠醖願夢 (選構衊襯遞築糧窪遞遞, 鹽憲鬱觸鹹積簾鑰淵糧 ~ 鬱製製餘廠壓遞範積顧) 更多	-	2011-06-20
				Placebo+Gelusil® (Placebo)	鏇顧構製壓顧網糧憲網(繭網衊淵襯網鹹選築鬱) = 製顧憲鹽廠夢積鏇餘鏇鏇鹽積淵壓鹹廠醖願夢 (選構衊襯遞築糧窪遞遞, 艱鬱築繭廠獵蓋願醖衊 ~ 衊夢繭積鹹艱壓網築襯) 更多